In this Trending News Europe episode, Jack, Jen, and Ollie discuss recent newsworthy items from across Europe, including the impact of and deterrents against “no shows” at medical appointments, the role bacteria play in cancer treatment, and inequalities in the rare disease market, along with the steps being taken to ease these issues.
Podcast Tags: healthcare, healthcare news, life sciences, public health, France, medical, bacteria, cancer, immunotherapy, chemotherapy, microbiome, rare disease, Germany, Italy, health disparity
Source Links:
- Dutch hospitals use AI to solve no-show patient problems that cost them millions
- Cancellations of NHS care are having serious impacts on two-thirds of patients
- Would charging patients for missed appointments help fund the NHS?
- GP ‘no shows’ cost Norfolk NHS more than 1m in a one month
- France planning €5 no-show fees in a bid to improve community healthcare
- France divided over ‘no-show tax’ for patients failing medical appointments
- Researchers compile detailed catalog of bacteria living in cancer metastases
- Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech
- The key to young onset bowel cancer may be gut bacteria
- The mystery of microbes that live inside tumours
- Diversity of Bacteria in Cancer Metastases
- It’s the Little Things: A Role for Bacteria in Cancer Treatment
- The UK is missing out on EU collaboration to improve treatment for rare diseases
- Overcoming the burden of rare diseases in Europe
- Stronger together in the fight against rare diseases
- Is Europe on track to be the leader in rare diseases?
- Right here, right now European public health policies must start giving people living with rare diseases a fair chance
- New rare diseases action plan on horizon, Europe at turning point
- Europe needs new 360 rare diseases strategy
Panel – Jack Young, Jen Burke, Ollie May
Recording & Editing – Mike Liberto, Rachel Skonecki
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.
Listen now
ASH® 2025 roundtable: Turning hematology innovation into real world progress
Insights from ASH® 2025 on hematology innovation, CAR-T, bispecifics, diagnostics, and how connected strategy supports real-world adoption.
Read moreChina’s ascendent role in oncology therapy innovation
China is emerging as a global oncology innovation hub, reshaping clinical development, dealmaking, and advanced therapy sourcing worldwide.
Read moreFrom high hopes to hesitation: Tracking the shifting barriers to alzheimer’s DMT adoption
Why Alzheimer’s DMT uptake remains low: Explore key barriers, diagnostic gaps, and market insights from 783 physicians worldwide.
Read more